Single-dose and multiple-dose pharmacokinetics and dose proportionality of intravenous and intramuscular HPβCD-diclofenac (Dyloject) compared with other diclofenac formulations

Pharmacotherapy

Volumn 33, Issue 10, 2013, Pages 1012-1021

  Mermelstein, Fred ^a,b   Hamilton, Douglas A ^a,c   Wright, Curtis ^a,d   Lacouture, Peter G ^e   Ramaiya, Atulkumar ^e   Carr, Daniel B ^a,f  

^a Javelin Pharmaceuticals Inc   (United States)

^b Leviathan Biopharma Group Inc Oncolupta Inc   (United States)

^c New Biology Ventures   (United States)

^d Rock Creek Pharmaceuticals Inc   (United States)

^e Hospira Inc   (United States)

^f TUFTS MEDICAL CENTER   (United States)

Author keywords

analgesia; diclofenac; Dyloject; hydroxypropyl cyclodextrin; intramuscular; intravenous; oral; pharmacokinetics; Voltarol

Indexed keywords

DICLOFENAC; DICLOFENAC POTASSIUM;

ADULT; ANEMIA; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DOSE PROPORTIONALITY; DOSE RESPONSE; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; FAINTNESS; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HUMAN EXPERIMENT; INJECTION SITE PAIN; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PATIENT COMPLIANCE; PHARMACOLOGICAL PARAMETERS; PLASMA CONCENTRATION-TIME CURVE; POSITIONAL DIZZINESS; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; SINGLE DRUG DOSE; SWEAT GLAND DISEASE; SWEATING; THROMBOPHLEBITIS; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION;

ANALGESIA; DICLOFENAC; DYLOJECT; HYDROXYPROPYL-Β-CYCLODEXTRIN; INTRAMUSCULAR; INTRAVENOUS; ORAL; PHARMACOKINETICS; VOLTAROL;

ADMINISTRATION, ORAL; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AREA UNDER CURVE; BETA-CYCLODEXTRINS; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DICLOFENAC; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCIPIENTS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAMUSCULAR; MALE;

EID: 84894242549     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1304     Document Type: Article

References (26)

1. Kawai S, Nishida S, Kato M, et al. Comparison of cyclooxygenase-1 and -2 inhibitory activities of various nonsteroidal anti-inflammatory drugs using human platelets and synovial cells. Eur J Pharmacol 1998; 347: 87-94.
2. Kato M, Nishida S, Kitasato H, Sakata N, Kawai S,. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs: investigation using human peripheral monocytes. J Pharm Pharmacol 2001; 53: 1679-85.
3. Peretz A, Degani N, Nachman R, et al. Meclofenamic acid and diclofenac, novel templates of KCNQ2/Q3 potassium channel openers, depress cortical neuron activity and exhibit anticonvulsant properties. Mol Pharmacol 2005; 67: 1053-66.
4. Claeys MA, Camu F, Maes V,. Prophylactic diclofenac infusions in major orthopedic surgery: effects on analgesia and acute phase proteins. Acta Anaesthesiol Scand 1992; 36: 270-5.
5. Hovorka J, Kallela H, Korttila K,. Effect of intravenous diclofenac on pain and recovery profile after day-case laparoscopy. Eur J Anaesthesiol 1993; 10: 105-8.
6. Hyrkas T, Ylipaavalniemi P, Oikarinen VJ, Paakkari I,. Preoperative intravenous Voltarol for postoperative pain prevention in outpatients. Br J Oral Maxillofac Surg 1993; 31: 351-4.
7. Novartis Pharmaceuticals UK Ltd. Voltarol® (diclofenac sodium) ampoules. Summary of product characteristics. Surrey, UK; 2004. Available from http://emc.medicines.org.uk/emc/assets/c/html/displaydoc.asp?documentid=1339. Accessed March 15, 2008.
8. Doenicke A, Nebauer AE, Hoernecke R, Mayer M, Roizen MF,. Osmolalities of propylene glycol-containing drug formulations for parenteral use. Should propylene glycol be used as a solvent? Anesth Analg 1992; 75: 431-5.
9. Rowe RC, Sheskey PJ, Weller PJ, eds. Handbook of pharmaceutical excipients. Washington, DC: American Pharmaceutical Association; 2003.
10. Campbell WI, Watters CH,. Venous sequelae following i.v. administration of diclofenac. Br J Anaesth 1989; 62: 545-7.
11. Lie C, Leung F, Chow SP,. Nicolau syndrome following intramuscular diclofenac administration: a case report. J Orthoped Surg 2006; 14: 104-7.
12. Stevens DA,. Itraconazole in cyclodextrin solution. Pharmacotherapy 1999; 19: 603-11.
13. Baker MT, Naguib M,. Propofol: the challenges of formulation. Anesthesiology 2005; 103: 860-76.
14. Javelin Pharmaceuticals. HPβCD-diclofenac summary of product characteristics. Cambridge, MA: Javelin Pharmaceuticals; 2007.
15. National Patient Safety Agency. Patient safety alert 20: Promoting safer use of injectable medicines. National Health Service (UK); 28 March, 2007. Available from www.npsa.nhs.uk.
16. Scott RJ, Palmer J, Lewis IA, Pleasance S,. Determination of a "GW cocktail" of cytochrome P450 probe substrates and their metabolites in plasma and urine using automated solid phase extraction and fast gradient liquid chromatography tandem mass spectrometry. Rapid Commun Mass Spectrom 1999; 13: 2305-19.
17. Dinley RJ,. Venous reactions related to indwelling plastic cannulae: a prospective clinical trial. Curr Med Res Opin 1976; 3: 607-11.
18. Guidance for Industry. Statistical approaches to establishing bioequivalence. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), January 2001.
19. Gould S, Scott RC,. 2-hydroxypropyl-β-cyclodextrin (HP-β-CD): a toxicology review. Food Chem Toxicol 2005; 43: 1451-9.
20. Stern WC,. Cyclodextrin-based drug delivery. Drug News Perspect 1989; 2: 410-5.
21. ® for postoperative dental pain. Reg Anesth Pain Med 2007; 32: 303-10.
22. ®, a novel injectable diclofenac solubilised with cyclodextrin: Reduced incidence of thrombophlebitis compared to injectable diclofenac solubilised with polyethylene glycol and benzyl alcohol. Acute Pain 2009; 11: 15-21.
23. Gibaldi M, Perrier D,. Pharmacokinetics. New York, NY: Marcel Dekker, 1975: 33-5.
24. Christensen K, Daniels S, Bandy D, et al. A double-blind, placebo-controlled comparison of a novel formulation of intravenous diclofenac and ketorolac for postoperative third molar extraction pain. Anesth Prog 2011; 58: 73-81.
25. Daniels S, Melson T, Hamilton DA, Lang E, Carr DB,. Analgesic efficacy and safety of a novel injectable formulation of diclofenac compared with intravenous ketorolac and placebo after orthopedic surgery: a multicenter, randomized, double-blinded, multiple-dose trial. Clin J Pain 2012 (In press). DOI: 10.1097/AJP.0b013e318270f957.
26. Wallerstein KRB,. A cost minimization analysis of IV bolus versus IV infusion Voltarol in post-operative pain. International Society for Pharmacoeconomic and Outcomes Research (ISOPOR); 10th Annual European Congress (Abstract PPN2), October 20-23, 2007; Dublin, Ireland.